Clinical Laserthermia Systems
4,903 SEK +4,99%1 investor følger denne virksomhed
Clinical Laserthermia Systems is a company active in medical technology. The company's vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as malignant melanoma, as well as cancer in the lungs, liver, and pancreas. The company was founded in 2006 and is headquartered in Lund.
Omsætning
8,27 mio.
EBIT %
-797,22 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CLS B
Daglig lav / høj pris
4,5 / 5,489
SEK
Markedsværdi
68,3 mio. SEK
Aktieomsætning
1,38 mio. SEK
Volumen
266 t
Finanskalender
Delårsrapport
31.10.2024
Årsrapport
21.02.2025
Delårsrapport
16.05.2025
Delårsrapport
15.08.2025
Delårsrapport
14.11.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Avanza Pension | 6,8 % | 6,8 % |
Nordnet Pensionsförsäkring | 6,7 % | 6,7 % |
Handelsbanken Liv Försäkringsaktiebolag | 5,6 % | 5,6 % |
Ålandsbanken | 3,9 % | 3,8 % |
Arne Håkanson | 2,6 % | 2,6 % |
Deutsche Bank AG | 2,5 % | 2,5 % |
Anders Berthag | 1,3 % | 1,3 % |
Rickard Danielsson | 1,1 % | 1,0 % |
Harry Sjöblom | 1,0 % | 1,0 % |
Sven Lennartsson | 1,0 % | 1,0 % |
ViserAlle indholdstyper
CLS: Bulletin from the Extraordinary General Meeting on 21st of October in Clinical Laserthermia Systems AB
CLS reschedules the publication of the Q3 2024 interim report to an earlier date and invites to a webcast
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools